Market closed
Oragenics Inc./$OGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
Ticker
$OGEN
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Employees
4
Website
Oragenics Inc. Metrics
BasicAdvanced
$4.1M
-
-$1.60
0.85
-
Price and volume
Market cap
$4.1M
Beta
0.85
52-week high
$0.31
52-week low
$0.16
Average daily volume
409K
Financial strength
Current ratio
0.874
Quick ratio
0.513
Total debt to equity
-155.05
Interest coverage (TTM)
-353.99%
Management effectiveness
Return on assets (TTM)
-204.98%
Return on equity (TTM)
-714.95%
Valuation
Price to book
-11.24
Price to tangible book (TTM)
-11.24
Price to free cash flow (TTM)
-0.146
Growth
Earnings per share change (TTM)
-82.62%
3-year earnings per share growth (CAGR)
-41.78%
Oragenics Inc. News
AllArticlesVideos
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
GlobeNewsWire·1 week ago
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
GlobeNewsWire·3 weeks ago
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Oragenics Inc. stock?
Oragenics Inc. (OGEN) has a market cap of $4.1M as of April 16, 2025.
What is the P/E ratio for Oragenics Inc. stock?
The price to earnings (P/E) ratio for Oragenics Inc. (OGEN) stock is 0 as of April 16, 2025.
Does Oragenics Inc. stock pay dividends?
No, Oragenics Inc. (OGEN) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Oragenics Inc. dividend payment date?
Oragenics Inc. (OGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Oragenics Inc.?
Oragenics Inc. (OGEN) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.